Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay–guided chemotherapy
- 1 November 2003
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 189 (5) , 1301-1307
- https://doi.org/10.1067/s0002-9378(03)00629-x
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Tumor chemosensitivity and chemoresistance assaysCancer, 1997
- Tumor chemosensitivity and chemoresistance assaysCancer, 1996
- Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1994
- Cancer of the OvaryNew England Journal of Medicine, 1993
- Second‐line chemotherapy for recurrent carcinoma of the ovaryCancer, 1993
- Prediction of Response to Drug Therapy of CancerDrugs, 1992
- selection of Cancer Chemotherapy for a Patient by an In Vitro Assay Versus a ClinicianJNCI Journal of the National Cancer Institute, 1990
- The cell biology of multiple drug resistanceBiochemical Pharmacology, 1987
- Primary Bioassay of Human Tumor Stem CellsScience, 1977